BridgeBio Oncology Therapeutics (BBOT) Q4 2025 earnings summary

Executive summary

• Debuted as a public oncology company with three clinical-stage small molecule inhibitors targeting the RAS pathway.

• Advanced all three internally discovered RAS and PI3Kα programs into clinical development in 2025.

• Preliminary safety and efficacy data across all programs support a differentiated therapeutic index and combination strategy.

• Cash runway expected to fund operations into 2028, supporting planned clinical milestones.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $425.5 million as of December 31, 2025.

• R&D expenses were $38.1M for Q4 2025 (up from $19.5M in Q4 2024) and $121.2M for FY 2025 (up from $73.1M in FY 2024).

• G&A expenses were $5.3M for Q4 2025 (up from $2.3M in Q4 2024) and $24.6M for FY 2025 (up from $7.8M in FY 2024).

• Net loss was $38.8M for Q4 2025 (vs. $19.7M in Q4 2024) and $134.0M for FY 2025 (vs. $74.3M in FY 2024).

Outlook and guidance

• Clinical readouts for all three programs expected in the second half of 2026.

• Internal combination cohort initiations and data readouts planned for late 2026.

• Cash runway projected to support operations into 2028.